Stereotactic ablative radiotherapy for early stage non-small cell lung cancer: A critical literature review of predictive factors of relapse

Cancer Treat Rev. 2016 Nov:50:240-246. doi: 10.1016/j.ctrv.2016.10.002. Epub 2016 Oct 13.

Abstract

Stereotactic ablative radiation therapy (SABR) has become the standard treatment for peripheral medically non-operable patients with early stage non-small cell lung cancer (NSCLC). Previous attempts of trials to compare SABR and surgery have failed and new randomized studies (SABRtooth, STABLEMATES, and VALOR) are ongoing. While predictive factors of relapse have been extensively studied in patients receiving surgery, there is scarce data on such putative factors in SABR patients. The purpose of this review is to analyze such predictive factors through a critical review of the literature.

Keywords: Local relapse; Lung cancer; Stereotactic ablative radiation therapy (SABR); Stereotactic body radiotherapy (SBRT); Surgery.

Publication types

  • Review

MeSH terms

  • Adenocarcinoma / diagnostic imaging
  • Adenocarcinoma / pathology
  • Adenocarcinoma / radiotherapy*
  • Carcinoma, Non-Small-Cell Lung / diagnostic imaging
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Carcinoma, Non-Small-Cell Lung / radiotherapy*
  • Carcinoma, Squamous Cell / diagnostic imaging
  • Carcinoma, Squamous Cell / pathology
  • Carcinoma, Squamous Cell / radiotherapy*
  • Humans
  • Lung Neoplasms / diagnostic imaging
  • Lung Neoplasms / pathology
  • Lung Neoplasms / radiotherapy*
  • Neoplasm Recurrence, Local / epidemiology*
  • Neoplasm Staging
  • Positron Emission Tomography Computed Tomography
  • Radiosurgery / methods*
  • Radiotherapy, Image-Guided
  • Risk Factors
  • Treatment Outcome
  • Tumor Burden